MedPharm's Record Growth Funds New R&D Laboratories.UK Pharmaceutical Development Specialist Responds to Increased Demand for MedSpray and MedNail Topical Delivery Technologies LONDON -- UK pharmaceutical research and development specialist MedPharm Ltd today announced that it is to move R&D operations from London to new R&D laboratories on the Surrey Research Park The Surrey Research Park is located in Guildford, Surrey, UK close to the A3 road and the Royal Surrey County Hospital. The park is owned and run by the University of Surrey[1]. , Guildford, UK (30 miles S.W. of London). The move will be completed by mid- October and is in response to increased demand for both the company's general pharmaceutical development services (formulation and analytical) and its innovative topical delivery technologies in particular MedSpray[TM] and MedNail. MedPharm's (CRO) contract business has had another successful year of growth, with an increase in revenue of over 20%. This rise in business has been a key driver in the company's relocation in order to ensure the continued expansion of MedPharm. Announcing the move, MedPharm CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr Andrew Muddle Muddle - Original name of MDL. , commented: "Since its inception as a university spin-out, MedPharm has operated R&D from laboratories in Kings College, London. Whilst this was the perfect location for establishing MedPharm during our early years, MedPharm has grown at such a pace over the least two years that our own dedicated R&D facilities has become essential. Refurbishment re·fur·bish tr.v. re·fur·bished, re·fur·bish·ing, re·fur·bish·es To make clean, bright, or fresh again; renovate. re·fur of the new laboratories on the Surrey Research Park has provided us with an excellent base to service both our current and planned future growth. Our client portfolio is now well balanced between major pharma and upcoming biotech companies, both in Europe and the US. In particular, we are seeing increased demand for our two topical delivery solutions MedSpray and MedNail which has resulted in the requirement of additional development activities and capabilities. Our new location is in a prime position for easy access for our national and international clients with close proximity to London airports There are several airports that may be referred to as "London Airport": London, United Kingdom
MedSpray is a topical spray drug delivery system and MedNail technology to substantially improve ungal drug delivery solution as Dr. Muddle explained: "Our initial target for MedSpray is the dermatology dermatology (dûrmətŏl`əjē), branch of medicine concerned with diagnosis and treatment of diseases and disorders of the skin. market, which continues to grow at record rates. Spray technology has the potential to become one of the delivery methods of choice in the dermatology market due to its increased patient acceptance and consumer appeal, particularly among the young. MedSpray will be attractive to all companies active in the sector. The MedSpray technology enables the reformulation of existing drugs with the ability to improve their delivery whilst reducing the dosing regimen. This results in the development of effective innovative products with an extended patent life. In addition to initiating a number of clinical development projects ourselves, MedPharm is currently performing evaluation studies for several leading companies in the dermatology field. MedNail shows similar promise in a market where existing oral formulations have significant side effects Side effects Effects of a proposed project on other parts of the firm. . Again several evaluation studies are also underway." Notes to editors: MedPharm is a specialist pharmaceutical development company that is recognized internationally, particularly for its expertise in topical (skin, nail, mucous membranes Mucous membranes The inner tissue that covers or lines body cavities or canals open to the outside, such as nose and mouth. These membranes secrete mucus and absorb water and salts. Mentioned in: Leprosy, Pulmonary Fibrosis, Topical Anesthesia ) and airway airway /air·way/ (-wa) 1. the passage by which air enters and leaves the lungs. 2. a device for securing unobstructed respiration. delivery systems. Established in 1999 and with over 60 customers worldwide, MedPharm has build a reputation for its unique and highly specialized service in contract research and development, together with expert project management. Projects range from simple feasibility tests, dosage design and optimization, through to preparation of GMP GMP (guanosine monophosphate): see guanine. clinical supplies for Phase I/II trials with guaranteed smooth transfer through to manufacturing sites. MedPharm has GLP See gateway location protocol. accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. laboratories in Guildford Surrey, UK and a GMP facility in the South of England. The company has a substantial patent portfolio of novel drug delivery systems, some of which, for example in topical formulations, it is exploiting in its internal drug development programme. These technologies are also available, either as part of the service offering or as stand-alone licences, to third parties for developing their own compounds in non-competing indications. In addition, MedPharm is actively seeking to license out that IP, for example, in novel formulations for pulmonary drug delivery, for which it is planning no further internal development. New Address, MedPharm R&D centre, Unit 3, Chancellor Court, 50 Occam Road, Surrey Research Park, Guildford, Surrey, GU27YN. More information can be found at www.medpharm.co.uk. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion